"skipMainNavigation"
Search
Quick Search in Journals
Quick Search anywhere
Advanced Search
Radiology
The logo for the journal RadioGraphics
The logo for the journal Radiology: Imaging Cancer
The logo for the journal Radiology: Cardiothoracic Imaging
The logo for the journal Radiology: Artificial Intelligence
Menu
Previous
Next
Genitourinary Imaging

Urinary Bladder Cancer: Preoperative Nodal Staging with Ferumoxtran-10–enhanced MR Imaging

Published Online:Nov 1 2004https://doi.org/10.1148/radiol.2332031111

Abstract

PURPOSE: To prospectively evaluate ferumoxtran-10–enhanced magnetic resonance (MR) imaging for nodal staging in patients with urinary bladder cancer.

MATERIALS AND METHODS: Fifty-eight patients with proved bladder cancer were enrolled. Results of MR imaging performed before and after injection of ferumoxtran-10 were compared with histopathologic results in surgically removed lymph nodes. High-spatial-resolution three-dimensional T1-weighted magnetization-prepared rapid acquisition gradient-echo (voxel size, 1.4 × 1.4 × 1.4 mm) and T2*-weighted gradient-echo (voxel size, 0.8 × 0.8 × 3.0 mm) sequences were performed before and 24 hours after injection of ferumoxtran-10 (2.6 mg iron per kilogram of body weight). On precontrast images, lymph nodes were defined as malignant by using size and shape criteria (round node, >8 mm; oval, >10 mm axial diameter). On postcontrast images, nodes were considered benign if there was homogeneous decrease in signal intensity and malignant if decrease was absent or heterogeneous. Qualitative evaluation was performed on a node-to-node basis. Sensitivity, specificity, predictive values, and accuracy were evaluated with logistic regression analysis.

RESULTS: In 58 patients, 172 nodes imaged with use of ferumoxtran-10 were matched and correlated with results of node dissection. Of these, 122 were benign and 50 were malignant. With nodal size and shape criteria, accuracy, sensitivity, specificity, and positive and negative predictive values on precontrast images were 92%, 76%, 99%, 97%, and 91%, respectively; corresponding values on postcontrast images were 95%, 96%, 95%, 89%, and 98%. In the depiction of pelvic metastases, sensitivity and negative predictive value improved significantly at postcontrast compared with those at precontrast imaging, from 76% to 96% (P < .001) and from 91% to 98% (P < .01), respectively. At postcontrast imaging, metastases (4–9 mm) were prospectively found in 10 of 12 normal-sized nodes (<10 mm); these metastases were not detected on precontrast images. Postcontrast images also showed lymph nodes that were missed at pelvic node dissection in two patients.

CONCLUSION: Ferumoxtran-10–enhanced MR imaging significantly improves nodal staging in patients with bladder cancer by depicting metastases even in normal-sized lymph nodes.

© RSNA, 2004

References

  • 1 Barentsz JO, Jager GJ, Witjes JA. MR imaging of the urinary bladder. Magn Reson Imaging Clin N Am 2000; 8:853-867.
    Medline Google Scholar
  • 2 Jager GJ, Barentsz JO, Oosterhof G, et al. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional T1-weighted magnetization-prepared rapid gradient-echo sequence. AJR Am J Roentgenol 1996; 167:1503-1507.
    Medline Google Scholar
  • 3 Barentsz JO, Jager GJ, van Vierzen PB, et al. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. Radiology 1996; 201:185-193.
    Google Scholar
  • 4 Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343:254-261.
    Medline Google Scholar
  • 5 Bellin MF. Iron oxide-enhanced MR lymphography: initial experience. Eur J Radiol 2000; 34:257-264.
    Medline Google Scholar
  • 6 Harisinghani MG, Saini S, Weissleder R, et al. MR lymphangiography using USPIO in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. AJR Am J Roentgenol 1999; 172:1347-1351.
    Medline Google Scholar
  • 7 Harisinghani M, Barentsz J, Hahn P, et al. Non-invasive detection of clinically occult lymph-node metastasis in prostate cancer. N Engl J Med 2003; 348:2491-2499.
    Medline Google Scholar
  • 8 Sobin LH, Wittekind CH, eds. International Union Against Cancer (UICC): TNM classification of malignant tumors New York, NY: Wiley-Liss, 1997; 170- 173.
    Google Scholar
  • 9 Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19:666-675.
    Medline Google Scholar
  • 10 Herr HW, Bochner BH, Dalbagni G, et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002; 167:1295-1298.
    Medline Google Scholar
  • 11 Herr HW. Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology 2003; 61:105-108.
    Medline Google Scholar
  • 12 Wolf JS, Cher M, Dall’era M, et al. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 1995; 153:993-999.
    Medline Google Scholar
  • 13 Scheidler J, Hricak H, Yu KK, et al. Radiological evaluation of lymph node metastases in patients with cervical cancer. JAMA 1997; 278:1096-1101.
    Medline Google Scholar
  • 14 Dooms GC, Hricak H, Crooks LE, et al. Magnetic resonance imaging of the lymph nodes: comparison with CT. Radiology 1984; 153:719-728.
    Google Scholar
  • 15 Dooms GC, Hricak H, Mosely MR, et al. Characterization of lymphadenopathy by magnetic relaxation times: preliminary results. Radiology 1985; 155:691-697.
    Google Scholar
  • 16 Bachor R, Kotzerke J, Reske SN, et al. Lymph node staging of bladder neck carcinoma with positron emission tomography. Urologe 1999; 38:46-50.
    Medline Google Scholar
  • 17 Bellin MF, Roy C, Kinkel K, et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamanetic iron oxide particles—initial clinical experience. Radiology 1998; 207:799-808.
    Google Scholar
  • 18 Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall paramagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990; 175:494-498.
    Google Scholar
  • 19 Vassallo P, Matei C, Heston WDW, et al. AMI-227-enhanced MR lymphography: usefulness for differentiating reactive from tumor bearing lymph nodes. Radiology 1994; 193:501-506.
    Google Scholar
  • 20 Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986; 31:288-305.
    Medline Google Scholar
  • 21 Guimaraes R, Clement O, Bittoun J, et al. MR lymphography with super paramagnetic nanoparticles in rats: pathologic basis for contrast enhancement. AJR Am J Roentgenol 1994; 162:201-207.
    Medline Google Scholar
  • 22 Chambon C, Clement O, Le Blanche A, et al. Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. Magn Reson Imaging 1993; 11:509-519.
    Medline Google Scholar
  • 23 Hudgins PA, Anzai Y, Christino A, et al. Dextran-coated superparamagnetic iron oxide MR contrast agent (Combidex) for imaging cervical lymph nodes: optimal dose, time of imaging, and pulse sequence (abstr) Proceedings of the 34th Annual Meeting of the American Society of Neuroradiology. Oak Brook, Ill: American Society of Neuroradiology, 1996; 24.
    Google Scholar
  • 24 Anzai Y, Blackwell K, Hirschowitz S, et al. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology 1994; 192:709-715.
    Google Scholar
  • 25 Stets C, Brandt S, Wallis F, et al. Axillary lymph node metastases: a statistical analysis of various parameters in MRI with USPIO. J Magn Reson Imaging 2002; 16:60-68.
    Medline Google Scholar
  • 26 Pannu HK, Wang KP, Borman TL, et al. MR imaging of mediastinal lymph nodes: evaluation using a superparamagnetic contrast agent. J Magn Reson Imaging 2000; 12:899-904.
    Medline Google Scholar
  • 27 Michel SC, Keller TM, Frohlich PH, et al. Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 2002; 225:527-536.
    Google Scholar
  • 28 Bellin MF, Leblue L, Meric JB. Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography. Abdom Imaging 2003; 28:155-163.
    Medline Google Scholar
  • 29 Reinhardt MJ, Ehritt-Braun C, Vogelsnag D, et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR Imaging and FDG PET. Radiology 2001; 218:776-778.
    Google Scholar
  • 30 Leissner J, Allhof EP, Hohenfeller R, et al. Significance of pelvic lymphadenectomy for the prognosis after radical cystectomy. Zentralbl Chir 2002; 127:315-332.
    Medline Google Scholar
  • 31 Mills RD. Pelvic lymph node metastases from bladder cancer outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol 2001; 166:19-23.
    Medline Google Scholar
  • 32 Harisinghani MG, Barentsz JO, Hahn PF, et al. MR lymphangiography for detection of minimal nodal disease in patients with prostate cancer (abstr). Radiology 2001; 221(P):387.
    Google Scholar

Article History

Published in print: Nov 2004